Antibodies News and Research

RSS

SARS-CoV-2 antibodies in breast milk: Study

A new study published on the medRxiv* preprint server explores the presence of immunoglobulin (Ig) antibodies IgA and IgG against SARS-CoV-2 in breast milk secreted by women with confirmed infection. The scientists also delineated the specific antigens targeted by the antibodies.

26 Jul 2021

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

In a research paper recently uploaded to the preprint server bioRxiv by Tada et al. (July 19th, 2021) the neutralizing capacity of antibodies generated by either messenger RNA (mRNA) or adenoviral vector-based vaccines against Beta, Delta, Delta plus, and Lambda variants are investigated, among others, highlighting the importance of continued SARS-CoV-2 genomic surveillance.

26 Jul 2021

Novel atlas charts how different antibodies attack a major piece of SARS-CoV-2 machinery

As the SARS-CoV-2 virus that causes COVID-19 continues to evolve, immunologists and infectious diseases experts are eager to know whether new variants are resistant to the human antibodies that recognized initial versions of the virus.

26 Jul 2021

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

A recent study conducted as a part of the Real-Time Assessment of Community Transmission-2 (REACT-2) program has estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies among adult populations in England.

25 Jul 2021

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

A new study discusses how both different responses to the infection itself and to COVID-19 vaccines are likely the result of genetic differences.

25 Jul 2021

Study receives $15 million CDC award to continue research on COVID-19 immunity, vaccine effectiveness

A University of Arizona Health Sciences study of COVID-19 vaccine effectiveness and immunity among frontline workers has received a $15 million award from the U.S. Centers for Disease Control and Prevention (CDC) to continue the current research for another year and expand to include children and focus on underserved populations.

23 Jul 2021

Research uncovers an unexpected role for immune T cells in protection against malaria

Advanced technologies have been used to solve a long-standing mystery about why some people develop serious illness when they are infected with the malaria parasite, while others carry the infection asymptomatically.

23 Jul 2021

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

23 Jul 2021

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

A new study has been published on the bioRxiv* preprint server, which has identified and characterized two RBD-targeting neutralizing nanobodies, namely, DL4 and DL28.

23 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Iain Chapple, University of Birmingham, England, presented the oral session "Longitudinal Serological and Vaccination Responses to SARS-COV-2 in Dental Professionals" at the virtual 99th General Session & Exhibition of the International Association for Dental Research (IADR), held in conjunction with the 50th Annual Meeting of the American Association for Dental Research (AADR) and the 45th Annual Meeting of the Canadian Association for Dental Research (CADR), on July 21-24, 2021.

23 Jul 2021

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Researchers in Canada have reported the discovery of a multi-antibody cocktail that synergistically protected against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an animal model of acute infection.

22 Jul 2021

Innovative testing platform could enable more precise, personalized immunotherapy

An innovative testing platform that more closely mimics what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells.

22 Jul 2021

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Scientists have developed a 'nanobody' - a small fragment of a llama antibody - that is capable of chasing out human cytomegalovirus (HCMV) as it hides away from the immune system.

22 Jul 2021

Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern

A nationwide case-control study conducted in France has assessed the efficacy of mRNA-based coronavirus disease 2019 (COVID-19) vaccines against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, including B.1.1.7, B.1.351, and P1.

22 Jul 2021

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

A new study, recently released as a preprint on the medRxiv* server, reports the intriguing finding that the cross-neutralizing antibodies elicited by human seasonal coronaviruses (sCoVs) show varying ability to prevent binding between the SARS-CoV-2 spike antigen and its cognate receptor, the angiotensin-converting enzyme 2 (ACE2).

22 Jul 2021

Big leagues balk at endorsing vaccination

Santa Clara County, where the San Francisco 49ers train and play their NFL home games, has one of the highest covid vaccination rates in California.

22 Jul 2021

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

The study, published in the journal Cell Host & Microbe, also showed emerging mutations L452R and Y453F in the SARS-CoV-2 spike receptor-binding motif evade (HLA) A24-restricted cellular immunity. Meanwhile, the L452R enhances spike stability, viral fusogenicity, and viral infectivity. Hence, the findings suggest that HLA-restricted cellular immunity potentially affects the evolution of viral phenotypes.

22 Jul 2021

SARS-CoV-2 genomic surveillance identifies intricacies of stabilizing vs. destabilizing mutations

Some of these variants, known as variants of concern (VoC), have a much higher rate of transmission and increased mortality than the original SARS-CoV-2 strain. Therefore, it is imperative to assess the efficacy of the available vaccines against the circulating SARS-CoV-2 strains. In addition, tracking the continuously evolving genetic variants is also vital to prevent future outbreaks.

22 Jul 2021

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

Researchers in the United States have conducted a study showing that while variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can compromise the effectiveness of single therapeutic antibodies at preventing severe coronavirus disease 2019 (COVID-19), many combination antibody products remain potent against the variants.

21 Jul 2021

Antibodies News and Research

SARS-CoV-2 antibodies in breast milk: Study

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines against variants of concern

Novel atlas charts how different antibodies attack a major piece of SARS-CoV-2 machinery

5.6% seroprevalence of SARS-CoV-2 antibodies in England during second wave

CD8+ T cells show gene-dependent variation in cross-reactivity to human coronaviruses

Study receives $15 million CDC award to continue research on COVID-19 immunity, vaccine effectiveness

Research uncovers an unexpected role for immune T cells in protection against malaria

Advantages and challenges of intranasal vaccines to fight against COVID-19 infections

Researchers discover camelid-derived two nanobodies that target SARS-CoV-2

Clinical trials during a pandemic – lessons from COVID-19

SARS-COV-2 infection leads to neutralizing and protective serological responses in over 70% of DPs

Synergistic multi-antibody cocktail protects against SARS-CoV-2 in animal model

Innovative testing platform could enable more precise, personalized immunotherapy

Llama ‘nanobodies’ have the potential to outwit human cytomegalovirus

Study in France suggests high efficacy of mRNA vaccines against SARS-CoV-2 variants of concern

Can prior human seasonal coronavirus antibody response patterns predict SARS-CoV-2 inhibition?

Big leagues balk at endorsing vaccination

Emerging SARS-CoV-2 mutations L452R & Y453F evade cellular immunity

SARS-CoV-2 genomic surveillance identifies intricacies of stabilizing vs. destabilizing mutations

Combination antibody therapies retain potency against SARS-CoV-2 variants, FDA / HHS research

How to make hybridoma-based antibody discovery more efficient eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News